financetom
Business
financetom
/
Business
/
Salesforce Tops Third-Quarter Revenue Views, Updates Full-Year Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Salesforce Tops Third-Quarter Revenue Views, Updates Full-Year Outlook
Dec 3, 2024 2:11 PM

04:47 PM EST, 12/03/2024 (MT Newswires) -- Salesforce ( CRM ) late Tuesday reported fiscal third-quarter revenue that surpassed Wall Street's estimates amid gains in subscription and support sales.

Revenue gained 8% to $9.44 billion, above the $9.35 billion consensus compiled by FactSet. Adjusted per-share earnings rose to $2.41 during the three months ended Oct. 31 from $2.11 a year earlier.

Shares were up 5% in after-hours trading.

Subscription and support revenue increased 9% to $8.88 billion, while professional services and other fell to $565 million from $579 million.

Salesforce ( CRM ) said it now expects fiscal 2025 revenue at $37.8 billion to $38 billion, raising the low end of the prior guidance from $37.7 billion. Analysts polled by FactSet expect $37.85 billion in full-year sales.

The company forecasts adjusted EPS of $9.98 to $10.03 this year, compared with $10.03 to $10.11 previously expected.

For the current quarter, Salesforce ( CRM ) projects adjusted EPS of $2.57 to $2.62 on revenue between $9.9 billion to $10.1 billion, which would reflect 7% to 9% year-over-year growth. The Street is projecting $10.05 billion in sales.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cycle Pharmaceuticals Offers to Buy Vanda Pharmaceuticals for $466 Million
Cycle Pharmaceuticals Offers to Buy Vanda Pharmaceuticals for $466 Million
Jun 6, 2024
09:02 AM EDT, 06/06/2024 (MT Newswires) -- Vanda Pharmaceuticals ( VNDA ) has received an acquisition proposal from Cycle Pharmaceuticals to buy 100% of Vanda's shares for $466 million in cash, or $8 per share, Cycle Pharmaceuticals said Thursday. The offer, proposed to Vanda's board on May 24, represents a 58% premium above Vanda's closing share price on June 5,...
SECURE Energy Announced Preliminary Results of Its Substantial Issuer Bid
SECURE Energy Announced Preliminary Results of Its Substantial Issuer Bid
Jun 6, 2024
09:00 AM EDT, 06/06/2024 (MT Newswires) -- SECURE Energy Services Inc. ( SECYF ) on Thursday announced preliminary results of its substantial issuer bid, pursuant to which it offered to purchase for cancellation up to $250 million of its outstanding common shares from holders of shares for cash. The offer expired at 5pm (Eastern time) on June 5, 2024. In...
Dolby Laboratories Acquires GE Licensing for $429 Million
Dolby Laboratories Acquires GE Licensing for $429 Million
Jun 6, 2024
09:00 AM EDT, 06/06/2024 (MT Newswires) -- Dolby Laboratories ( DLB ) said Thursday that it had acquired GE Licensing, an intellectual property licensing business, from GE Aerospace (GE), for $429 million in cash. Dolby ( DLB ) said GE Aerospace would keep its aerospace and defense IP and the GE brand trademarks. Dolby said the deal, slated to be...
BRIEF-Dolby Laboratories Announces Agreement to Acquire GE Licensing from GE Aerospace
BRIEF-Dolby Laboratories Announces Agreement to Acquire GE Licensing from GE Aerospace
Jun 6, 2024
June 6 (Reuters) - Dolby Laboratories Inc ( DLB ): * DOLBY LABORATORIES ANNOUNCES AGREEMENT TO ACQUIRE GE LICENSING FROM GE AEROSPACE * DOLBY LABORATORIES INC ( DLB ) - PROPOSED DEAL FOR $429 MILLION ALL CASH TRANSACTION * DOLBY LABORATORIES INC ( DLB ) - DOLBY EXPECTS DEAL TO BE ACCRETIVE ON A NON GAAP BASIS TO OPERATING MARGINS...
Copyright 2023-2026 - www.financetom.com All Rights Reserved